John Vavricka - 31 Jan 2023 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Role
Chief Commercial Officer
Signature
/s/ Andrea Corcoran, as Attorney-in-Fact for John Vavricka
Issuer symbol
AVIR
Transactions as of
31 Jan 2023
Net transactions value
$0
Form type
4
Filing time
02 Feb 2023, 17:26:43 UTC
Previous filing
02 Feb 2022
Next filing
02 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVIR Restricted Stock Units Award $0 +100,000 $0.000000 100,000 31 Jan 2023 Common Stock 100,000 Direct F1, F2
transaction AVIR Stock Option (Right to Buy) Award $0 +140,000 $0.000000 140,000 31 Jan 2023 Common Stock 140,000 $4.63 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026.
F3 The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2023 such that the option is fully vested on January 31, 2027.